The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
and there's something called invocell has your research exposed you to this no invocell is a way to try to take IVF into making it more financially accessible for certain patient populations mainly people who don't ovulate like your very refractory PCOS patient who doesn't respond to medication or who have tubal Factor infertility
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
that being said the young patient who's got great egg quality who might have really bad PCOS or tubal disease it can certainly allow them the opportunity for a child at a lower price point when they still have many reproductive years to finalize their family